Nektar Therapeutics (NKTR) Tops Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- Lockheed Martin to acquire Ultra Maritime for $3.45 billion
- Broadcom, Apple extend chip supply deal through 2031
- Strategy reports $8.32B bitcoin loss and sells BTC to fund dividends
Nektar Therapeutics (NKTR) PT Raised to $35 at Jefferies; Plans '181 NDA 2 Years Early
November 8, 2017 8:28 AM ESTJefferies raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $35.00 (from $23.00) while maintaining a Buy rating following Q3 results.
Analyst David Steinberg said the big news was NKTR disclosed that they are now planning to file an NDA for 181 in Apr... More
